Pharmaceutics (May 2021)

Hsa-miR-125b Therapeutic Role in Colon Cancer Is Dependent on the Mutation Status of the TP53 Gene

  • Diana Cenariu,
  • Alina-Andreea Zimta,
  • Raluca Munteanu,
  • Anca Onaciu,
  • Cristian Silviu Moldovan,
  • Ancuta Jurj,
  • Lajos Raduly,
  • Alin Moldovan,
  • Adrian Florea,
  • Liviuta Budisan,
  • Laura Ancuta Pop,
  • Lorand Magdo,
  • Mihai Tudor Albu,
  • Rares Bogdan Tonea,
  • Mihai-Stefan Muresan,
  • Calin Ionescu,
  • Bogdan Petrut,
  • Rares Buiga,
  • Alexandru Irimie,
  • Diana Gulei,
  • Ioana Berindan-Neagoe

DOI
https://doi.org/10.3390/pharmaceutics13050664
Journal volume & issue
Vol. 13, no. 5
p. 664

Abstract

Read online

Colon cancer is the third most common cancer type worldwide and is highly dependent on DNA mutations that progressively appear and accumulate in the normal colon epithelium. Mutations in the TP53 gene appear in approximately half of these patients and have significant implications in disease progression and response to therapy. miR-125b-5p is a controversial microRNA with a dual role in cancer that has been reported to target specifically TP53 in colon adenocarcinomas. Our study investigated the differential therapeutic effect of miR-125b-5p replacement in colon cancer based on the TP53 mutation status of colon cancer cell lines. In TP53 mutated models, miR-125b-5p overexpression slows cancer cells’ malignant behavior by inhibiting the invasion/migration and colony formation capacity via direct downregulation of mutated TP53. In TP53 wild type cells, the exogenous modulation of miR-125b-5p did not significantly affect the molecular and phenotypic profile. In conclusion, our data show that miR-125b-5p has an anti-cancer effect only in TP53 mutated colon cancer cells, explaining partially the dual behavior of this microRNA in malignant pathologies.

Keywords